Abstract 838P
Background
Axi-cel, a chimeric antigen receptor T-cell (CAR T) therapy evaluated in ZUMA-1, and epcor, a bispecific antibody evaluated in EPCORE NHL-1, are treatments for R/R LBCL. In the absence of a head-to-head trial, we conducted an unanchored MAIC to estimate relative treatment effects of axi-cel versus epcor in 3L+ R/R LBCL.
Methods
ZUMA-1 patient-level data were matched (using a logistic propensity score model) to baseline characteristics representing pre-specified clinically relevant prognostic factors in EPCORE NHL-1 (N=157): International Prognostic Index score, ECOG performance status, disease stage, response to last therapy, number of prior lines, primary refractoriness, LBCL subtype, and prior autologous stem cell transplant. Outcomes were objective response rate (ORR), duration of response (DOR), progression-free survival (PFS), overall survival (OS), and grade ≥3 cytokine release syndrome (G3+ CRS). Neurotoxicity was not analysed as definitions differed. Relative effects were hazard/odds ratios (HR/OR). Base case analyses included ZUMA-1 pivotal Cohorts 1+2 (C12; N=101). Scenario analyses of OS and CRS added ZUMA-1 safety Cohorts 4+6 (C1246; N=182).
Results
The effective sample size (ESS) for axi-cel was 30 in the base-case (Table). Axi-cel improved PFS (median 12.5 months) versus epcor (median 4.4 months). ORR, DOR and OS results were comparable with point estimates favoring axi-cel. A higher rate of G3+ CRS was associated with axi-cel but the difference was reduced in the scenario analysis.
Table: 838P
MAIC results
Outcome | Weighted axi-cel versus epcoritamab (95% confidence interval) | |
Base case (C12) ESS=30 | Scenario (C1246) ESS=43 | |
ORR OR | 1.55 (0.65−3.69) | N/A |
PFS HR | 0.51 (0.31−0.85) | N/A |
DOR HR | 0.84 (0.46−1.52) | N/A |
OS HR | 0.77 (0.45−1.30) | 0.67 (0.41−1.10) |
G3+ CRS OR | 5.31 (1.21−23.32) | 4.43 (1.10−17.92) |
Conclusions
Our MAIC suggests axi-cel may be more efficacious in terms of PFS versus epcor but with a higher risk of CRS G3+. Of note, median follow-up was short in EPCORE NHL-1 (10.7 months) compared to ZUMA-1 (60 months [C12] and 24 months [C46]) and differences in prior CAR T exposure could not be adjusted for (39% in EPCORE NHL-1 vs 0% in ZUMA-1).
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Kite, a Gilead Company.
Funding
Kite, a Gilead Company.
Disclosure
O.O. Oluwole: Financial Interests, Institutional, Advisory Role, Scientific advisory role and consultant to Kite Pharma, Allogene, CERo Therapeutics, Novartis, BlueBird Bio, Bristol Myers Squibb, National Cancer Institute, Leukemia and Lymphoma Society: Kite Pharma. M.D. Ray, H. Smith, C.L. Bellasis Spooner, A.R. Patel: Financial Interests, Personal and Institutional, Full or part-time Employment, A stockholder and current employee of Kite, a Gilead company: Kite Pharma. J.M. Chen, K. Chan, I. Zhang, S. Keeping: Financial Interests, Institutional, Full or part-time Employment, PRECISIONheor received consulting fees from Kite, a Gilead Company: PRECISIONheor. F.L. Locke: Financial Interests, Institutional, Advisory Role, Honoraria from Gilead and Pfizer; scientific advisory role and consultant for AbbVie, ADC, Curio Science, Epizyme, Gilead, Janssen, Kite, a Gilead Company, Pfizer, Nektar, Novartis, Syncopation, and TGR therapeutics: Kite Pharma.
Resources from the same session
1000P - Real-world clinical outcomes of cabozantinib (cabo) as a second-line (2L) treatment for advanced hepatocellular carcinoma (aHCC)
Presenter: Daniel Ahn
Session: Poster session 18
1001P - Patients’ prioritization of treatment goals in hepatocellular carcinoma (HCC): A global qualitative observational study (PERIDOT)
Presenter: Marcus-Alexander Wörns
Session: Poster session 18
1002P - Efficacy and safety of tislelizumab combined with TKIs and FOLFOX4-HAIC in conversion therapy of unresectable hepatocellular carcinoma
Presenter: Kai Tan
Session: Poster session 18
1003P - Efficacy and safety of triple combination therapy with transarterial chemoembolization (TACE), tyrosine kinase inhibitor (TKI), and immune checkpoint inhibitor (ICI) versus dual combination therapy in unresectable hepatocellular carcinoma (uHCC): A systematic review and meta-analysis
Presenter: Omar Maaño
Session: Poster session 18
1004P - Comparative efficacy of systemic sequential regorafenib after sorafenib or lenvatinib treatment failure for advanced hepatocellular carcinoma: A retrospective, multi-center, real-world study
Presenter: Danjun Song
Session: Poster session 18
1005P - Atezolizumab plus bevacizumab combined with transarterial chemoembolization and hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma with high tumor burden
Presenter: Jiliang Qiu
Session: Poster session 18
1006P - Associations of online search trends and prescription trends for hepatocellular carcinoma drugs
Presenter: Philipp Berning
Session: Poster session 18
1007P - Network meta-analysis (NMA) of lenvatinib vs key comparators in first-line unresectable hepatocellular carcinoma (uHCC)
Presenter: David Trueman
Session: Poster session 18